The pandemic of COVID-19 is predicted to have a major influence on the market. Multiple health officials, including the National Care Quality Commission Expertise (NICE), the National Health Service (NHS), the CDC, and the Ministry of Health and Family Welfare (MOHFW) of the Government of India, have preferred paracetamol for managing fever in adults and children with COVID-19 due to its widespread availability.
Furthermore, paracetamol is commonly utilised by people suffering from high fevers and flu-related aches and pains. Influenza is a year-round occurrence in tropical climates. The influenza season in the Northern Hemisphere normally begins in early fall, peaks in mid-February, and ends in late spring the following year. Influenza epidemics differ in length and severity based on the viral subtype involved. Annual influenza epidemics, according to the World Health Organization (2018), resulting in about 3-5 million instances of severe illness and 250,000 to 500,000 deaths worldwide.

Many different types of viruses can produce a typical cold. The illness is normally painless, and symptoms disappear in two weeks. Consumers rely on over-the-counter cough treatments as the first line of defence against cough symptoms. The sale of paracetamol medications for cough, cold, and flu has surged in high growth countries, such as India and China, because of the simplicity of procurement. Furthermore, one of the key factors for market expansion is an increase in the number of people suffering from pain and fever, as well as increased awareness.